A Phase 2a, 2-part,Randomized, Double-blind, Placebo-controlled, Incomplete Block Crossover Study to Evaluate the Safety and Efficacy of VX-371 Solution for Inhalation With and Without Oral Ivacaftor in Subjects With Primary Ciliary Dyskinesia
Phase of Trial: Phase II
Latest Information Update: 15 Oct 2017
At a glance
- Drugs P 1037 (Primary) ; Ivacaftor
- Indications Primary ciliary dyskinesia
- Focus Adverse reactions; Therapeutic Use
- Acronyms CLEAN-PCD
- Sponsors Parion Sciences; Vertex Pharmaceuticals
- 14 Apr 2017 Planned End Date changed from 1 Oct 2018 to 1 Apr 2019.
- 14 Apr 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Mar 2019.
- 12 Aug 2016 Status changed from not yet recruiting to recruiting.